Viewing nowCombinationOldipyong 5/20/12.5 mg
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.

MFDS item code 201903157 · Approved 2019.05.15 · Insurance code 693903010
Treatment of essential hypertension not controlled with dual combination therapy
The combination of amlodipine and olmesartan medoxomil is used in patients with essential hypertension who do not achieve adequate blood pressure control with existing treatment. This medication helps effectively lower blood pressure and reduce the risk of cardiovascular complications. Amlodipine dilates blood vessels to lower blood pressure, while olmesartan medoxomil prevents vessel constriction, synergizing blood pressure control. This combination therapy is more effective than single-agent therapy in controlling blood pressure. It is important for patients to take the medication consistently as prescribed and to periodically monitor blood pressure changes. This combination is effectively used for the treatment of essential hypertension.
Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine and olmesartan medoxomil as monotherapy or combination therapy) be adjusted before administering this medicine; however, direct switching to this medicine may be considered when blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil. The maximum dose of this medicine is 10/40/25mg as amlodipine/olmesartan medoxomil/hydrochlorothiazide. As the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. Recommended doses are as follows: - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose-escalation schedule. (The content of each component is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg ၀ Patients with renal impairment For patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min), the maximum dose of this medicine is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). ၀ Patients with hepatic impairment Caution should be exercised when administering this medicine to patients with mild or moderate hepatic impairment. The maximum dose of this medicine in patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. ၀ Older adults (65 years and older) Treatment should generally be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. As there is very limited experience with the use of this medicine in older adults 75 years of age and older, careful monitoring is required when it is administered.
The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.
This medication should be discontinued immediately if pregnancy occurs, as its use during the second and third trimesters can cause serious harm to the fetus and newborn. Patients with allergies or hypersensitivity to any ingredients in this medication or to similar classes of medications should not take it. It is also advisable for pregnant and nursing women not to use this medication. Patients with severe hypotension, severe valvular heart disease, unstable heart failure after acute myocardial infarction, or severe renal or hepatic impairment should not take this medication. In patients with decreased blood volume or electrolyte imbalance, hypotension may occur; therefore, careful monitoring of the patient's condition before administration and during treatment is necessary. Patients with poor renal function, kidney transplant patients, patients with renovascular hypertension, and those with impaired liver function may experience changes in renal and liver function, so regular check-ups are required during treatment. As this medication lowers blood pressure, dizziness or orthostatic hypotension may occur, and caution is needed when driving or operating hazardous machinery. This medication may interact with various other drugs; therefore, especially when taking lithium, NSAIDs, other antihypertensive drugs, or alcohol, consultation with a doctor or pharmacist is necessary. During the use of this medication, it is advisable to regularly check electrolyte levels and renal function through blood tests; if any unusual symptoms occur, inform healthcare professionals immediately. Photosensitivity may occur, so avoid excessive exposure to sunlight or ultraviolet rays. If any skin rash or itching develops, discontinue use and seek advice. In cases of overdose, severe hypotension or cardiac arrhythmias may occur, so it is important to adhere to the prescribed dosage and visit the hospital immediately if there are any suspicious symptoms. Safety and efficacy in children and adolescents under 18 years of age have not been established; therefore, use in these populations is not recommended. In the elderly, renal and liver functions may be impaired; hence, treatment should start with a lower dose and be closely monitored.
Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusional state, depression, indifference, irritability, anxiety, mood changes, sleep disturbances, orthostatic dizziness, syncope, taste disorders, hypertonicity, sensory impairment, paresthesia, peripheral neuropathy, drowsiness, syncope, seizures, loss of appetite, tremors, vision disturbances, reduced tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, bloating, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrent lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, increased frequency of urination, acute renal failure, hematuria, dysuria, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, apathy, edema, pain, facial swelling, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, increased gamma-glutamyl transferase, increased alanine aminotransferase, increased aspartate aminotransferase, elevated liver enzymes, increased creatine kinase in serum, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, pachyedema, asthenia, loss of consciousness, eczema, limb pain, mild decrease in mean hemoglobin and hematocrit levels, choroidal effusion, acute respiratory distress syndrome, acute angle-closure glaucoma, acute transient myopia
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. The storage temperature should be maintained between 1 degree and 30 degrees Celsius.
White and orange round film-coated tablets
30 tablets (10 tablets/Alu-Alu X 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg +1 more
Tablet · Prescription medication · Combination
Daicel Corporation (Co., Ltd.)
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg +1 more
Tablet · Prescription medication · Combination
HanKook Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate +1 more
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg +1 more
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.